Despite the absence of available molecularly targeted therapies in SCLC, the application of ADCs may represent a potential treatment strategy that takes advantage of the intrinsic molecular characteristics exhibited by the tumor cells, such as the overexpression of TROP2, DLL3, B7-H3, and CECAM5. The gene discussed is CD276; the disease is small cell lung carcinoma.